© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361
Affiliations of authors: Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, U.K. (CRC, SB, MAB, AHC, BWD, SK, DRN, EN, HDT, LZW, NJC); Pfizer Global Research and Development/Agouron Pharmaceuticals, La Jolla, CA (RA, SCK, ZH, RAK, JL, KM, DS, SEW); School of Pharmacy, University of Manchester, Manchester, U.K. (IJS, KJW).
Correspondence to: Nicola J. Curtin, PhD, Northern Institute for Cancer Research, University of Newcastle upon Tyne, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K. (e-mail: n.j.curtin{at}newcastle.ac.uk)
Background: Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks. Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy and radiation therapy in vitro. Because classical PARP-1 inhibitors have limited clinical utility, we investigated whether AG14361, a novel potent PARP-1 inhibitor (inhibition constant <5 nM), enhances the effects of chemotherapy and radiation therapy in human cancer cell cultures and xenografts. Methods: The effect of AG14361 on the antitumor activity of the DNA alkylating agent temozolomide, topoisomerase I poisons topotecan or irinotecan, or x-irradiation or 
-radiation was investigated in human cancer cell lines A549, LoVo, and SW620 by proliferation and survival assays and in xenografts in mice by tumor volume determination. The specificity of AG14361 for PARP-1 was investigated by microarray analysis and by antiproliferation and acute toxicity assays in PARP-1-/- and PARP-1+/+ cells and mice. After intraperitoneal administration, the concentration of AG14361 was determined in mouse plasma and tissues, and its effect on PARP-1 activity was determined in tumor homogenates. All statistical tests were two-sided. Results: AG14361 at 0.4 µM did not affect cancer cell gene expression or growth, but it did increase the antiproliferative activity of temozolomide (e.g., in LoVo cells by 5.5-fold, 95% confidence interval [CI] = 4.9-fold to 5.9-fold; P = .004) and topotecan (e.g., in LoVo cells by 1.6-fold, 95% CI = 1.3-fold to 1.9-fold; P = .002) and inhibited recovery from potentially lethal -radiation damage in LoVo cells by 73% (95% CI = 48% to 98%). In vivo, nontoxic doses of AG14361 increased the delay of LoVo xenograft growth induced by irinotecan, x-irradiation, or temozolomide by two- to threefold. The combination of AG14361 and temozolomide caused complete regression of SW620 xenograft tumors. AG14361 was retained in xenografts in which PARP-1 activity was inhibited by more than 75% for at least 4 hours. Conclusion: AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Melisi, V. Ossovskaya, C. Zhu, R. Rosa, J. Ling, P. M. Dougherty, B. M. Sherman, J. L. Abbruzzese, and P. J. Chiao Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity Clin. Cancer Res., October 15, 2009; 15(20): 6367 - 6377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ali, B. A. Telfer, C. McCrudden, M. O'Rourke, H. D. Thomas, M. Kamjoo, S. Kyle, T. Robson, C. Shaw, D. G. Hirst, et al. Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo? Clin. Cancer Res., October 1, 2009; 15(19): 6106 - 6112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Horton, G. Jenkins, D. Pati, L. Zhang, M. E. Dolan, A. Ribes-Zamora, A. A. Bertuch, S. M. Blaney, S. L. Delaney, M. Hegde, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity Mol. Cancer Ther., August 1, 2009; 8(8): 2232 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Gaymes, S. Shall, L. J. MacPherson, N. A. Twine, N. C. Lea, F. Farzaneh, and G. J. Mufti Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes Haematologica, May 1, 2009; 94(5): 638 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Ma and A. A. Adjei Novel Agents on the Horizon for Cancer Therapy CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chalmers The potential role and application of PARP inhibitors in cancer treatment Br. Med. Bull., March 1, 2009; 89(1): 23 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Daniel, A. L. Rozanska, H. D. Thomas, E. A. Mulligan, Y. Drew, D. J. Castelbuono, Z. Hostomsky, E. R. Plummer, A. V. Boddy, D. A. Tweddle, et al. Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma Clin. Cancer Res., February 15, 2009; 15(4): 1241 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Clarke, E. A. Mulligan, P. T. Grogan, A. C. Mladek, B. L. Carlson, M. A. Schroeder, N. J. Curtin, Z. Lou, P. A. Decker, W. Wu, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines Mol. Cancer Ther., February 1, 2009; 8(2): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Russo, H.-C. Kwon, W. E. Burgan, D. Carter, K. Beam, X. Weizheng, J. Zhang, B. S. Slusher, A. Chakravarti, P. J. Tofilon, et al. In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 Clin. Cancer Res., January 15, 2009; 15(2): 607 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al. Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7917 - 7923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Eltze, R. Boer, T. Wagner, S. Weinbrenner, M. C. McDonald, C. Thiemermann, A. Burkle, and T. Klein Imidazoquinolinone, Imidazopyridine, and Isoquinolindione Derivatives as Novel and Potent Inhibitors of the Poly(ADP-ribose) Polymerase (PARP): A Comparison with Standard PARP Inhibitors Mol. Pharmacol., December 1, 2008; 74(6): 1587 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Beneke, O. Cohausz, M. Malanga, P. Boukamp, F. Althaus, and A. Burkle Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1 Nucleic Acids Res., November 1, 2008; 36(19): 6309 - 6317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Kinders, M. Hollingshead, S. Khin, L. Rubinstein, J. E. Tomaszewski, J. H. Doroshow, R. E. Parchment, and the National Cancer Institute Phase 0 Clinical Tri Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts Clin. Cancer Res., November 1, 2008; 14(21): 6877 - 6885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, Y. Shi, R. Guan, C. Donawho, Y. Luo, J. Palma, G.-d. Zhu, E. F. Johnson, L. E. Rodriguez, N. Ghoreishi-Haack, et al. Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks Mol. Cancer Res., October 1, 2008; 6(10): 1621 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Kyle, H D Thomas, J Mitchell, and N J Curtin Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S6 - S11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Plummer and H. Calvert Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Beneke and A. Burkle Poly(ADP-ribosyl)ation in mammalian ageing Nucleic Acids Res., December 3, 2007; 35(22): 7456 - 7465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Plummer and H. Calvert Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy Clin. Cancer Res., November 1, 2007; 13(21): 6252 - 6256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chu, H. Xu, T. J. Ferro, and P. X. Rivera Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1127 - L1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miknyoczki, H. Chang, J. Grobelny, S. Pritchard, C. Worrell, N. McGann, M. Ator, J. Husten, J. Deibold, R. Hudkins, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity Mol. Cancer Ther., August 1, 2007; 6(8): 2290 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Haince, S. Kozlov, V. L. Dawson, T. M. Dawson, M. J. Hendzel, M. F. Lavin, and G. G. Poirier Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents J. Biol. Chem., June 1, 2007; 282(22): 16441 - 16453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Albert, C. Cao, K. W. Kim, C. D. Willey, L. Geng, D. Xiao, H. Wang, A. Sandler, D. H. Johnson, A. D. Colevas, et al. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models Clin. Cancer Res., May 15, 2007; 13(10): 3033 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clin. Cancer Res., May 1, 2007; 13(9): 2728 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Thomas, C. R. Calabrese, M. A. Batey, S. Canan, Z. Hostomsky, S. Kyle, K. A. Maegley, D. R. Newell, D. Skalitzky, L.-Z. Wang, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial Mol. Cancer Ther., March 1, 2007; 6(3): 945 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ratnam and J. A. Low Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bentle, K. E. Reinicke, E. A. Bey, D. R. Spitz, and D. A. Boothman Calcium-dependent Modulation of Poly(ADP-ribose) Polymerase-1 Alters Cellular Metabolism and DNA Repair J. Biol. Chem., November 3, 2006; 281(44): 33684 - 33696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Wilson Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer Oncologist, October 1, 2006; 11(9): 1018 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tentori, C. Leonetti, M. Scarsella, A. Muzi, E. Mazzon, M. Vergati, O. Forini, R. Lapidus, W. Xu, A. S. Dorio, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma FASEB J, August 1, 2006; 20(10): 1709 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Martin-Oliva, R. Aguilar-Quesada, F. O'Valle, J. A. Munoz-Gamez, R. Martinez-Romero, R. Garcia del Moral, J. M. Ruiz de Almodovar, R. Villuendas, M. A. Piris, and F. J. Oliver Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis Cancer Res., June 1, 2006; 66(11): 5744 - 5756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, H. D. Thomas, M. A. Batey, I. G. Cowell, C. J. Richardson, R. J. Griffin, A. H. Calvert, D. R. Newell, G. C.M. Smith, and N. J. Curtin Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441. Cancer Res., May 15, 2006; 66(10): 5354 - 5362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Noel, C. Godon, M. Fernet, N. Giocanti, F. Megnin-Chanet, and V. Favaudon Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther., March 1, 2006; 5(3): 564 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Poonepalli, L. Balakrishnan, A. K. Khaw, G. K. M. Low, M. Jayapal, R. N. Bhattacharjee, S. Akira, A. S. Balajee, and M. P. Hande Lack of Poly(ADP-Ribose) Polymerase-1 Gene Product Enhances Cellular Sensitivity to Arsenite Cancer Res., December 1, 2005; 65(23): 10977 - 10983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Smith, E. Willmore, C. A. Austin, and N. J. Curtin The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks Clin. Cancer Res., December 1, 2005; 11(23): 8449 - 8457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hay, H. Jenkins, O. J. Sansom, N. M.B. Martin, G. C.M. Smith, and A. R. Clarke Efficient Deletion of Normal Brca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy Cancer Res., November 15, 2005; 65(22): 10145 - 10148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Plummer, M. R. Middleton, C. Jones, A. Olsen, I. Hickson, P. McHugh, G. P. Margison, G. McGown, M. Thorncroft, A. J. Watson, et al. Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 Clin. Cancer Res., May 1, 2005; 11(9): 3402 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Catley, Y.-T. Tai, R. Shringarpure, R. Burger, M. T. Son, K. Podar, P. Tassone, D. Chauhan, T. Hideshima, L. Denis, et al. Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma Cancer Res., December 1, 2004; 64(23): 8746 - 8753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, et al. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells Clin. Cancer Res., February 1, 2004; 10(3): 881 - 889. [Abstract] [Full Text] [PDF]
|
|